Comparison of pegfilgrastim on day 2 vs. day 4 as primary prophylaxis of intense dose-dense chemotherapy in patients with node-positive primary breast cancer within the prospective, multi-center GAIN study: (GBG 33)

Supportive Care in Cancer

Volumn 19, Issue 11, 2011, Pages 1789-1795

  Loibl, Sibylle ^a   Mueller, Volkmar ^b   Von Minckwitz, Gunter ^a   Conrad, Bettina ^c   Koehne, Claus Henning ^d   Kremers, Stephan ^e   Forstbauer, Helmut ^f   Linder, Mattea ^a   Nekljudova, Valentina ^a   Moebus, Volker ^g  

^a GERMAN BREAST GROUP   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c Elisabeth Krankenhaus   (Germany)

^d KLINIKUM OLDENBURG   (Germany)

^e Caritas Krankenhaus Lebach   (Germany)

^f GOSPL Gesellschaft für onkologische Studien Hämatologie und Onkologie   (Germany)

^g Eye Hospital   (Germany)

Author keywords

Dose dense chemotherapy; Febrile; Leucopenia; Neutropenia; Pegfilgrastim; Primary breast cancer

Indexed keywords

CIPROFLOXACIN; CLEMASTINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; EPIRUBICIN; MESNA; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PACLITAXEL; RANITIDINE; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SEROTONIN 3 ANTAGONIST;

ADULT; AGED; ANEMIA; ARTICLE; BREAST CANCER; CLINICAL STUDY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HUMAN TISSUE; INFECTION; LEUKOCYTE COUNT; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NODE POSITIVE PRIMARY BREAST CANCER; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SINGLE DRUG DOSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; FEMALE; FEVER; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LEUKOPENIA; MIDDLE AGED; NEUTROPENIA; PACLITAXEL; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; TIME FACTORS; YOUNG ADULT;

EID: 83255176181     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-010-1020-9     Document Type: Article

References (21)

1. Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ et al (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21:1431-1439
2. Untch M, Möbus V, Kuhn W, Muck BR, Thomssen C, Bauerfeind I et al (2009) Intensive dose-dense chemotherapy compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer. J Clin Oncol 27:2938-2945
3. Möbus V, Jackisch C, Lück HJ, du Bois A, Thomssen C, Kurbacher C et al (2010) Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer (4+ LN): mature results of an AGO-phase-III study. J Clin Oncol 28:2874-2880
4. von Minckwitz G, Schwenkglenks M, Skacel T, Lyman GH, Pousa AL, Bacon P et al (2009) Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: results from an integrated analysis. Eur J Cancer 45:608-617
5. Aapro MS, Cameron DA, Pettengell R, Bohlius J, Crawford J, Ellis M et al (2006) EORTC guidelines for the use of granulocytecolony stimulating factor to reduce the incidence of chemotherapyinduced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 42:2433-2453
6. Aapro M, Schwenkglenks M, Lyman GH, Lopez Pousa A, Lawrinson S, Skacel T et al (2009) Pegfilgrastim primary prophylaxis vs. current practice neutropenia management in elderly breast cancer patients receiving chemotherapy. Crit Rev Oncol Hematol 74:203-210
7. von Minckwitz G, Kümmel S, du Bois A, Eiermann W, Eidtmann H, Gerber B et al (2008) Pegfilgrastim ± ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study. Ann Oncol 19:292-298
8. National Comprehensive Cancer Network (2010) Practice guidelines in oncology v.1.2010. Myeloid growth factors. Available at:http:// www.nccn.org/professionals/physician-gls/PDF/myeloid-growth. pdf. Accessed 21 Apr 2010
9. Renwick W, Pettengell R, Green M (2009) Use of filgrastim and pegfilgrastim to support delivery of chemotherapy: twenty years of clinical experience. BioDrugs 23:175-186
10. Hartmann F, Zeynalova S, Nickenig C, Reiser M, Lengfelder E, Duerk H et al (2007) Peg-filgrastim (Peg-F) on day 4 of (R-) CHOP-14 chemotherapy compared to day 2 in elderly patients with diffuse large B-cell lymphoma (DLBCL): results of a randomized trial of the German high-grade non-Hodgkin's lymphoma study group (DSHNHL). J Clin Oncol 25(18S):19511
11. Whitworth JM, Matthews KS, Shipman KA, Numnum TM, Kendrick JE, Kilgore LC et al (2009) The safety and efficacy of day 1 versus day 2 administration of pegfilgrastim in patients receiving myelosuppressive chemotherapy for gynecologic malignancies. Gynecol Oncol 112:601-604
12. Skarlos DV, Timotheadou E, Galani E, Samantas E, Grimani I, Lianos E et al (2009) Pegfilgrastim administered on the same day with dose-dense adjuvant chemotherapy for breast cancer is associated with a higher incidence of febrile neutropenia as compared to conventional growth factor support: matched case- control study of the Hellenic Cooperative Oncology Group. Oncology 77:107-112
13. ® (pegfilgrastim) prescribing information. Amgen, Thousand Oaks
14. Loibl S, Nekljudova N, Skacel T, Schwenkglenks M, Lück HJ, Brodowicz T, Zielinski C, von Minckwitz G (2009) Evaluating the impact of relative total dose intensity (RTDI) on patient's shortand long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer: a pooled analysis. J Clin Oncol 27(15S):1065
15. Vose JM, Crump M, Lazarus H, Emmanouilides C, Schenkein D, Moore J et al (2003) Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. J Clin Oncol 21:514-519
16. Green MD, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P et al (2003) A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 14:29-35
17. Saven A, Schwartzberg L, Kaywin P, Bartlett N, Dean L, Shahin S et al (2006) Randomized, double blind phase II study evaluated same-day vs. next-day administration of pegfilgrastim with RCHOP in non-Hodgkin's lymphoma patients. J Clin Oncol 24 (suppl 18S):7570, abstr. 568
18. Möbus V, Conrad B, Schneeweiss A, Kreienberg R, Solomayer EF, Clemens MR et al (2009) Gain study: a phase III trial to compare ETC versus EC-TX and ibandronate versus observation in patients with node-positive primary breast cancer. J Clin Oncol 27(15S):568
19. Crawford J, Blackwell S, Bjurstrom T, Lockbaum P, Roskos L et al (2000) Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol 18:2522-2528
20. Holmes FA, O'Shaughnessy JA, Vukelja S, Jones SE, Shogan J, Savin M et al (2002) Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 20:727-731
21. Fox E, Widemann BC, Hawkins DS, Jayaprakash N, Dagher R, Aikin AA et al (2009) Randomized trial and pharmacokinetic study of pegfilgrastim versus filgrastim after dose-intensive chemotherapy in young adults and children with sarcomas. Clin Cancer Res 15:7361-7367